Adicet Bio, Inc’s Post

We are pleased that ADI-270, the first ever #gammadelta 1 CAR T #celltherapy candidate to enter #clinicaltrials for solid tumors, has been granted Fast Track Designation by the FDA. First trial is in renal cell carcinoma, the most common type of kidney cancer. This significant milestone underscores our commitment to advancing innovative treatments to patients as quickly as possible. Check out the press release here: https://lnkd.in/gRUwpHPm #allogeneic #CART #TCellRx #celltherapy #renalcellcarcinoma #RCC #Research #clinicaltrial #clinicaltrials #cancer #oncology #biotechnology #biotech

In Our Week in Review… we’re excited about the IND clearance for ADI-270, the first ever #gammadelta 1 CAR T cell therapy candidate to enter clinical trials for the treatment of #solidtumors. The successful IND clearance of this #armored CD70-targeted CAR gamma delta T cell for the treatment of renal cell carcinoma is the result of our team’s deep commitment to advancing science on behalf of #patients. Many thanks to all at Adicet Bio, Inc who worked on this -- we look forward to seeing the continued progress of this program of behalf of the patients we serve. https://lnkd.in/gpB6pba5 #allogeneic #CART #TCellRx #celltherapy #renalcellcarcinoma #RCC #Research #clinicaltrial #clinicaltrials #cancer #oncology #biotechnology #biotech

Adicet Chief Scientific Officer Blake Aftab will serve as one of the top thought leaders at the 6th Annual Allogeneic Cell Therapies Summit! He’ll join the Industry Leaders Fireside Chat to review the latest advances in the allogeneic cell therapy space, celebrating this year’s significant wins and charting the strategy for continuing progress in #research and development moving forward.  #allogeneic #celltherapy #CART #clinicaltrials #biotech #biotechnology

Thank you to #LupusTherapeutics, Lupus Research Alliance and all attendees at this year's #LuCINCommunity Meeting. It's an honor to collaborate with this dedicated community of passionate researchers, industry peers and people with #lupus focused on a mission to ensure that all people with lupus receive equitable access to safe and effective therapies.   #LupusAwarenessMonth #LupusClinicalResearch #autoimmune #gammadelta #celltherapy

We are pleased for our Chief Medical Officer, Francesco Galimi, MD PhD, to join other global thought leaders at the 1st International Autoimmune CAR T Innovators Summit this weekend in Grassau, Germany!   We’re excited to exchange ideas among global CAR T experts through presentations on basic research, clinical studies, and case reports, to tackle the challenges facing the treatment of autoimmune diseases today.    Exploring how CAR T cell therapy may help drive innovation, we’re applying our collective insights to create a paradigm shift in the treatment landscape to positively impact patients’ lives.    #CART #autoimmune #celltherapy #gammadelta #innovation #leadership

Adicet is honored to support #WorldLupusDay! We stand with the #lupuscommunity and celebrate the progress being made in #LupusClinicalResearch.   Today's discussions at the #LupusTherapeutics #LuCINCommunity Meeting around new approaches to cell therapy for autoimmune disease provide hope for the future of #lupus treatment.   Participation in research and increasing access to #clinicaltrials is critical to the development of more effective therapies in #lupus.   Learn more about Adicet’s clinical trial in lupus nephritis at https://lnkd.in/esC4winc and about the Lupus Research Alliance at https://bit.ly/LuCIN2024   #LupusAwarenessMonth #WorldLupusDay #CAR T #autoimmune #gammadelta #celltherapy

Adicet announced today new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70-positive cancers. Data were shared by Shon Green (our VP of Nonclinical Development) in an oral presentation at the ASGCT 27th Annual Meeting’s Targeted Gene and Cell Therapy session, co-chaired by Adicet’s Chief Scientific Officer, Blake Aftab.   ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform and is further enhanced with armoring to address suppressive tumor microenvironments and clearance by host T cells.   These preclinical data showed robust anti-tumor activity in multiple CD70-positive solid and hematological cancer models, and a potential for enhanced functional potency and resilience in the tumor microenvironment.   Findings from this study also provided comparative benchmarking for the mechanisms by which ADI-270 provides this enhanced functionality, potency and anti-tumor effect in CD70-positive expressing tumors such as clear cell renal cell carcinoma (ccRCC). With these data, Adicet plans to file an investigational new drug (IND) application for ADI-270 this quarter. #ASGCT2024 #gammadelta #CART #celltherapy #biotechnology #oncology #cancer

Thrilled to be here with #LupusTherapeutics and Lupus Research Alliance at the fourth annual Lupus Clinical Investigators Network (LuCIN) Community Meeting, bringing together clinical investigators, study coordinators, people with lupus and industry partners to participate in discussions around critical research initiatives and the latest approaches in lupus treatment.   Visit https://bit.ly/LuCIN2024 to learn more about LuCIN and https://lnkd.in/esC4winc to learn more about participating in Adicet Bio, Inc's lupus nephritis clinical trial.   #LupusClinicalResearch #LuCINCommunity #LupusAwarenessMonth #celltherapy #gammadelta #CART #autoimmune 

The Lupus Accelerating Breakthroughs Consortium (#LupusABC) today announced its expanded partnership with the Center for Biologics Evaluation and Research (CBER) at the consortium's first anniversary meeting. CBER's participation in Lupus ABC will help facilitate the creation and deployment of patient-focused tools and approaches in the development of CAR-T cell and other engineered cell therapies to ensure a focus on the most pressing questions for advancement of the field. Public-Private partnerships can be crucial in advancing drug development and patient care, and Adicet Bio, Inc is pleased to support these efforts. We encourage you to learn more at lupusresearch.org #lupus #lupusvoices #celltherapy #autoimmune #advancinglupusresearch #advancingpatientcare